Hillhouse backs Elpiscience's $35M round

Elpiscience Biopharma Ltd. (Shanghai, China) raised $35 million in a series A+ round led by Hillhouse Capital Management. Existing investor Lilly Asia Ventures and CDH Investments also participated in the round.

Elpiscience is stocking its oncology pipeline through a mix of business development and internal R&D using an in-house suite of immunological assays to gauge how compounds affect key parameters like T cell exhaustion, NK cell cytotoxicity and myeloid-derived suppressor cell (MDSC) activity (see "Brake for Gas")...